ICON plc – FDA 483, Oct 24, 2025

Between October 20 and October 24, 2025, the U.S. Food and Drug Administration (FDA) conducted an inspection of ICON plc, a bioanalytical facility located in Assen, Netherlands. The inspection identified critical deficiencies in the facility"s bioanalytical method validation processes. Specifically, the FDA observed that ICON plc failed to adequately evaluate the specificity of its testing methods when multiple medications were administered simultaneously. While the facility tested for potential interference from paracetamol, it did not assess the impact of other drugs used by study participants, such as cetirizine and several hormonal contraceptives including desogestrel and ethinyl estradiol. This oversight raises concerns regarding the accuracy and reliability of the study data, as the presence of these additional substances could potentially interfere with the measurement of the target compounds. This inspection was performed under the regulatory framework of Section 704(b) of the Federal Food, Drug, and Cosmetic (FD&C) Act, which empowers the FDA to monitor facilities for practices that could compromise data integrity. Although the Form FDA 483 represents preliminary observations and not a final determination, the company is expected to respond. ICON plc must provide a detailed plan of corrective actions to address these validation gaps and ensure that all future bioanalytical methods are sufficiently tested against all relevant co-administered medications.